A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
Filamon LTD
University of Florida
Jonsson Comprehensive Cancer Center
Novartis
Cancer Research UK
Centre Hospitalier Universitaire de Nīmes
British Columbia Cancer Agency
Washington University School of Medicine
Medicenna Therapeutics, Inc.
DEKA Biosciences
Columbia University
University of Arizona
Revolution Medicines, Inc.
Stanford University
Cedars-Sinai Medical Center
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
Klus Pharma Inc.
Revolution Medicines, Inc.
Bristol-Myers Squibb
Revolution Medicines, Inc.
Ohio State University Comprehensive Cancer Center
Lumos Pharma
Stanford University
sigma-tau i.f.r. S.p.A.
Santa Maria Biotherapeutics
BIND Therapeutics
Emory University
Calando Pharmaceuticals
New Mexico Cancer Research Alliance
Hoag Memorial Hospital Presbyterian
Netherlands Open University
Fujian Longhua Pharmaceutical Co. Ltd
NS Pharma, Inc.